GLP-1 and Hidradenitis Suppurativa: What the Evidence Shows

Hidradenitis suppurativa (HS) is a chronic inflammatory follicular disease affecting the axillae, groin, buttocks, and under-breast skin—not a simple bacterial infection you can scrub away. Early clinical data, alongside the strong link between HS severity, obesity, insulin resistance, and metabolic syndrome, indicate that GLP-1 receptor agonists are being studied as metabolic adjuncts. Small studies and case series suggest fewer flares alongside weight loss, but they are not standalone cures and do not replace topical treatments, systemic antibiotics, or biologics. When patients sit across from my desk searching for relief from painful, recurrent nodules, we look past outdated myths of poor hygiene and examine the deep roots of systemic inflammation.

Pathophysiology: Unpacking the Roots of Hidradenitis Suppurativa

To understand why metabolic therapies like GLP-1 receptor agonists intersect with dermatology, we must examine what happens beneath the surface of the skin. HS is fundamentally a disease of the hair follicle. The process begins with follicular hyperkeratosis—an abnormal shedding of skin cells inside the hair follicle. These cells clump together, creating a keratin plug that blocks the follicular opening.

As sebum and bacteria accumulate behind the plug, the follicle swells under pressure. Eventually, the wall ruptures, spilling keratin, bacteria, and cellular debris into the surrounding dermis. This triggers a massive, localized immune response. Neutrophils, macrophages, and T-cells flood the area, releasing pro-inflammatory cytokines such as interleukin-17 (IL-17) and tumor necrosis factor-alpha (TNF-alpha). Over time, this chronic immune overactivity creates painful nodules, deep abscesses, sinus tracts (tunnels beneath the skin), and permanent scarring.

Microbiome shifts and biofilm formation also play a role. While HS is not an infectious disease caught from someone else, the trapped environment inside these tunnels fosters polymicrobial communities. Mechanical factors add fuel to the fire. Friction, moisture, heat, and mechanical shear—especially in skin folds like the groin and armpits—stimulate further follicular rupture. Simple measures like wearing loose, breathable clothing and managing moisture help reduce these mechanical triggers, though they rarely halt the disease on their own.

Dermatologists rely on Hurley staging to classify disease severity:

• Stage I: Single or multiple isolated abscesses without scarring or sinus tracts.
• Stage II: Recurrent abscesses with the formation of sinus tracts and scarring, separated by normal skin.
• Stage III: Diffuse or broad involvement across a regional area with interconnected sinus tracts and abscesses.

The Comorbidity Map: Why HS Reaches Beyond the Skin

HS rarely travels alone. In clinical practice, I view HS not merely as a skin condition, but as a systemic inflammatory disorder. Patients frequently present with a complex web of metabolic and immune-mediated comorbidities. Obesity is a primary driver; adipose tissue is not inert fat, but an active endocrine organ that secretes inflammatory signaling molecules called adipokines.

Insulin resistance and hyperinsulinemia also plague a significant portion of HS patients. High circulating insulin levels stimulate androgen production and upregulate follicular cell proliferation, worsening the plugging process. This metabolic profile closely mirrors what we see in polycystic ovary syndrome (PCOS)—a condition with recognized links to both metabolic dysfunction and skin inflammation, as explored in discussions on GLP-1 and PCOS.

Furthermore, systemic inflammation does not stop at the skin. There is a well-documented epidemiological overlap between HS and inflammatory bowel disease (IBD), particularly Crohn's disease. Both conditions share overlapping genetic susceptibilities and dysregulated Th17 immune pathways, a topic frequently highlighted in our GLP-1 IBD connections. Patients also face higher rates of depression, anxiety, spondyloarthropathy, and other immune-mediated inflammatory conditions, much like the overlap seen in GLP-1 psoriasis and systemic inflammation and related concerns discussed in GLP-1 pilonidal disease.

What the Clinical Evidence Actually Shows About GLP-1 and Hidradenitis Suppurativa

Given the heavy metabolic burden associated with the condition, researchers and clinicians are closely evaluating the role of glp 1 hidradenitis suppurativa management strategies. Let us be entirely transparent about the current state of the science: there are no large-scale, randomized controlled trials establishing GLP-1 receptor agonists (such as semaglutide or tirzepatide) as FDA-approved primary treatments for HS.

However, retrospective case series and clinical observations reveal promising signals. Patients taking GLP-1 medications for type 2 diabetes or weight management frequently report a notable reduction in HS flare frequency and severity. How do these medications help?

1. Weight Loss and Mechanical Relief: Shedding excess pounds reduces skin-on-skin contact, decreases friction in the axillae and groin, and lowers mechanical shear stress on vulnerable follicles.
2. Reduction of Systemic Inflammation: GLP-1 receptor agonists exert direct anti-inflammatory effects on immune cells, suppressing macrophage activation and lowering circulating inflammatory cytokines.
3. Improved Insulin Sensitivity: Lowering insulin levels reduces the hormonal stimulation that drives follicular hyperkeratosis and plugging.

Despite these benefits, GLP-1 medications are adjuncts, not replacements. They do not substitute for targeted dermatologic therapies when managing active abscesses or established sinus tracts.

Managing Nutrition, Gut Health, and GI Side Effects on GLP-1s

When incorporating metabolic therapies into an HS management plan, gastrointestinal health requires careful attention. GLP-1 medications slow gastric emptying and alter gut motility, which can trigger nausea, bloating, constipation, or diarrhea. For patients with perianal HS lesions or co-existing Crohn's disease, managing bowel regularity is particularly delicate, as straining during constipation or experiencing frequent loose stools can severely irritate sensitive perianal tissue.

Additionally, appetite suppression can make it difficult to consume adequate protein and micronutrients essential for skin repair. Zinc and protein are building blocks for dermal wound healing. When dietary intake drops, healing slows.

To support digestive wellness and ensure comfort while on metabolic therapy, I often recommend gentle, targeted support:

For patients navigating slowed gastric motility and digestive sluggishness, incorporating a supportive supplement such as the GLP-1 Digestive Enzyme Companion can ease post-meal fullness and optimize nutrient breakdown.

To maintain healthy bowel regularity without irritating the gut or perianal tissues, a gentle, soluble fiber source like the Psyllium Fiber Supplement is often helpful in my clinical practice.

Balancing the intestinal microbiome during periods of systemic inflammation and medication adjustment can also benefit from a quality daily formula, such as Advanced Probiotics GI Support.

Graded Treatments and Lifestyle Levers for Managing HS

Managing hidradenitis suppurativa requires a tiered approach that matches therapy to disease severity. We build our treatment plans using a graded framework:

• Topical and Local Care: For mild Hurley Stage I disease, topical clindamycin lotion and antiseptic washes containing chlorhexidine help control local bacterial load and reduce surface inflammation.
• Systemic Antibiotics: Oral tetracyclines (such as doxycycline) offer both antimicrobial and anti-inflammatory properties. For more stubborn cases, a combination of oral clindamycin and rifampicin is frequently prescribed.
• Hormonal Therapy: Spironolactone helps block androgen receptors, while metformin addresses insulin resistance, proving particularly useful for female patients with overlapping PCOS or metabolic syndrome.
• Biologics: Targeted biologic therapies—specifically anti-TNF agents like adalimumab and anti-IL-17 agents like secukinumab—interrupt the specific immune pathways driving moderate-to-severe tissue destruction.
• Surgical Interventions: Procedures range from intralesional steroid injections for acute inflammatory nodules to surgical deroofing (unroofing sinus tracts) and wide local excision for advanced, scarring disease. Laser hair reduction is also useful early on to destroy the hair follicles where the disease originates.

What does not work? Repeated simple incision and drainage (I&D) of chronic nodules as a standalone treatment. While I&D offers immediate pain relief for an acute abscess, it fails to remove the underlying epithelialized sinus tract, guaranteeing that the abscess will return in the exact same spot. Aggressive physical scrubbing and harsh antibacterial soaps also fail; they damage the skin barrier and worsen inflammation. Furthermore, blaming poor hygiene is entirely inaccurate and causes unnecessary psychological distress.

When discussing lifestyle levers, smoking cessation remains the single highest-yield intervention. Nicotine promotes follicular hyperkeratosis and alters neutrophil function, making smokers significantly more resistant to standard medical therapy. Regarding diet, evidence is modest but clinically relevant: reducing high-glycemic foods and dairy products helps some patients lower systemic insulin spikes and subsequent flare frequency, while eliminating brewer's yeast remains largely anecdotal.

Comparison of Hidradenitis Suppurativa Interventions

Intervention	Primary Target	Evidence Strength	Time to Benefit	Who Prescribes
Topical Antibiotics (Clindamycin)	Superficial inflammation & bacteria	Moderate (Stage I)	2 to 4 weeks	Dermatologist / PCP
Oral Tetracyclines	Systemic inflammation & mild lesions	Strong	6 to 12 weeks	Dermatologist / PCP
Clindamycin + Rifampicin	Deep resistant bacterial colonization	Strong	4 to 10 weeks	Dermatologist
Biologics (Adalimumab / Secukinumab)	Specific cytokine pathways (TNF-α, IL-17)	Very Strong	12 to 16 weeks	Dermatologist
Surgical Deroofing / Excision	Chronic sinus tracts & scar tissue	Strong (for Stage II/III)	Immediate post-op healing	Dermatologic Surgeon / Colorectal Surgeon
Metabolic Therapy (GLP-1 / Metformin)	Insulin resistance, weight, metabolic inflammation	Emerging / Moderate	3 to 6 months	Endocrinologist / PCP / Weight Specialist

Red Flag Symptoms Requiring Immediate Evaluation

While managing chronic HS is a marathon, certain acute signs require prompt medical attention. Never ignore the following red flags:

• Rapidly Spreading Cellulitis or Systemic Fever: High fever combined with rapidly expanding redness, warmth, and severe pain can signal secondary bacterial sepsis requiring emergency care.
• Severe, Unrelenting Pain: Excruciating pain disproportionate to the visible size of a nodule may indicate deep tissue necrosis or a large concealed abscess tracking along fascial planes.
• Suspicion of Malignancy: Long-standing, chronic, non-healing scars and sinus tracts carry a small but real lifetime risk of developing squamous cell carcinoma. Any hard, rolled-edge ulceration within a chronic scar must be biopsied immediately.
• New Bowel Symptoms: Persistent abdominal pain, chronic diarrhea, or rectal bleeding in an HS patient should be evaluated promptly for inflammatory bowel disease like Crohn's disease.

Frequently Asked Questions About GLP-1 and Hidradenitis Suppurativa

Can Ozempic treat hidradenitis suppurativa?

Ozempic (semaglutide) and similar GLP-1 medications are not FDA-approved treatments for HS. However, because they promote significant weight loss and lower systemic inflammation and insulin resistance, many patients experience fewer and less severe flares. They work best as metabolic adjuncts alongside conventional dermatologic care.

Is HS caused by being overweight?

No, obesity does not cause HS. HS is primarily driven by follicular occlusion and immune system dysregulation. However, excess weight and insulin resistance significantly worsen the condition by increasing mechanical friction, sweating, and systemic inflammatory cytokines.

Does diet help manage hidradenitis suppurativa?

Dietary modifications offer modest support for some individuals. Reducing high-glycemic carbohydrates and dairy products can help stabilize insulin and hormone levels that influence follicular plugging. Complete elimination diets should be approached cautiously to prevent nutritional deficiencies.

Why do abscesses keep coming back after drainage?

Simple incision and drainage only relieves acute fluid pressure; it leaves the underlying epithelialized sinus tract intact. Because the structural tunnel remains, the blocked follicle continues to accumulate debris, causing the abscess to recur in the exact same location. Permanent resolution requires unroofing, excision, or targeted medical therapy.

Should I see dermatology or surgery?

You should ideally see both working in coordination. A dermatologist manages systemic medical therapy, biologics, and hormonal options. A dermatologic or general surgeon handles advanced procedures like deroofing, sinus tract excision, and management of extensive scarring.

Is HS linked to Crohn's disease?

Yes. HS shares a well-documented epidemiological and genetic link with inflammatory bowel disease, particularly Crohn's disease. Both conditions involve shared immune pathways, notably involving Th17 cell dysregulation, meaning patients with severe HS should report any persistent gastrointestinal symptoms to their physician.

---

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or qualified healthcare provider with any questions regarding a medical condition.

About the Author:
Dr. Onikepe Adegbola, MD PhD, is a Johns Hopkins-trained physician-scientist, molecular biologist, and gut health expert. She is the founder of Casa de Sante, where she combines rigorous clinical science with evidence-based nutritional care to support patients managing metabolic and gastrointestinal health.